Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Robert Rottapel"'
Autor:
John M. S. Bartlett, Arian Khandani, Alexandra Wudwud, Oliver Fung, Omar Subedar, Mikhail Bashkurov, Andras Kapus, Blaise A. Clarke, Patricia Shaw, Robert Rottapel, Tony Yeung
Publikováno v:
Oncotarget
Yeung, T, Fung, O, Bashkurov, M, Khandani, A, Subedar, O, Wudwud, A, Shaw, P, Clarke, B, Bartlett, J, Rottapel, R & Kapus, A 2019, ' Avoidance of apoptotic death via a hyperploid salvage survival pathway after platinum treatment in high grade serous carcinoma cell line models ', Oncotarget, vol. 10, no. 62, pp. 6691-6712 . https://doi.org/10.18632/oncotarget.27330
Scopus-Elsevier
Yeung, T, Fung, O, Bashkurov, M, Khandani, A, Subedar, O, Wudwud, A, Shaw, P, Clarke, B, Bartlett, J, Rottapel, R & Kapus, A 2019, ' Avoidance of apoptotic death via a hyperploid salvage survival pathway after platinum treatment in high grade serous carcinoma cell line models ', Oncotarget, vol. 10, no. 62, pp. 6691-6712 . https://doi.org/10.18632/oncotarget.27330
Scopus-Elsevier
The alkylating agent platinum is first-line chemotherapy treatment for high-grade serous carcinomas (HGSC) of tubal-ovarian origin. Platinum compounds cause DNA damage and induce apoptotic cell death in the bulk tumor population. However, subpopulati
Autor:
Ben X. Wang, Pamela S. Ohashi, Anthony Fyles, Linh T. Nguyen, Di Maria Jiang, Srikala S. Sridhar, Adrian G. Sacher, Robert Rottapel, Benjamin G. Neel
Publikováno v:
Oncotarget
Immunotherapy has shown modest activity in metastatic breast cancer (MBC). In this phase I dose escalation study, we assessed safety of tremelimumab, a humanized anti-CTLA4 monoclonal antibody, at starting dose 3 mg/kg, on the third day of palliative
Publikováno v:
Oncotarget
// Oliver A. Kent 1 , Maria-Jose Sandi 1 , Helen E. Burston 1 , Kevin R. Brown 2 , Robert Rottapel 1, 3, 4, 5, 6 1 Princess Margaret Cancer Centre, University Health Network, Toronto Medical Discovery Tower, University of Toronto, Toronto, Canada 2 D